Oct 2026
Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.
The interplay between the repertoire of antigens presented by the tumor and the breadth of induced immunity seemed to dictate clinical efficacy following vaccination, and this was associated with broader tumor and vaccine-specific immune responses in blood and tumor following vaccination.
Maclean C. Sellars, Jessica A. Frank, Bohoon Shim et al.
· Nature Medicine · 0 citations